• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Expert views
  • From 10 grams to several hundred – A case study in peptide GMP process development

From 10 grams to several hundred – A case study in peptide GMP process development

17 October 2022
Expert views

Presentation from TIDES digital week, September 2022, by Niall McLoughlin, PhD, Development Project Chemist at PolyPeptide Group.[…]

As a Contract Development & Manufacturing Organization (CDMO) of GMP-grade peptides, a central activity at PolyPeptide Laboratories is the development of robust and scalable manufacturing processes. Here, we present a case study describing the process development and the first GMP production of a 25-mer linear peptide which had only ever been previously manufactured in non-GMP batches up to 10 grams. We provide insight into a typical process development cycle and underline the key criteria which allowed for the definition of synthesis and purification conditions. Informed by results of our process development, we show how small adjustments applied to the GMP production campaign significantly improved both the yield and purity, enabling the isolation of several hundred grams of peptide API.

 

Back to news

Related posts

2 April 2025

Expanding the Reach of Sustainable Solid-Phase Peptide Synthesis


Read more
20 March 2025

Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase


Read more
13 November 2024

Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers